CUREVAC NV (5CV.DE) Stock Overview
FRA:5CV - NL0015436031 - Common Stock
5CV.DE Key Statistics, Chart & Performance
The current stock price of 5CV.DE is 4.62 EUR. In the past month the price decreased by -2.08%. In the past year, price increased by 61.65%.
5CV.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 19.6 | 314.09B | ||
| AMG.DE | AMGEN INC | 13.2 | 132.71B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.63 | 120.33B | ||
| 1VRTX.MI | VERTEX PHARMACEUTICALS INC | N/A | 86.48B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 23.11 | 85.98B | ||
| ARGX.BR | ARGENX SE | 81.62 | 36.96B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.70B | ||
| 1BIIB.MI | BIOGEN INC | 8.75 | 17.58B | ||
| IDP.DE | BIOGEN INC | 8.39 | 16.86B | ||
| 1EXEL.MI | EXELIXIS INC | 17.49 | 8.97B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.13B | ||
| 0QF.DE | MODERNA INC | N/A | 7.94B |
Related stock screener links
About 5CV.DE
Company Profile
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Company Info
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG DE
Employees: 825
Phone: 49707198830
CUREVAC NV / 5CV.DE FAQ
What is the stock price of CUREVAC NV today?
The current stock price of 5CV.DE is 4.62 EUR. The price decreased by -0.47% in the last trading session.
What is the ticker symbol for CUREVAC NV stock?
The exchange symbol of CUREVAC NV is 5CV and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is 5CV.DE stock listed?
5CV.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for CUREVAC NV stock?
13 analysts have analysed 5CV.DE and the average price target is 4.22 EUR. This implies a price decrease of -8.66% is expected in the next year compared to the current price of 4.62. Check the CUREVAC NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CUREVAC NV worth?
CUREVAC NV (5CV.DE) has a market capitalization of 1.04B EUR. This makes 5CV.DE a Small Cap stock.
How many employees does CUREVAC NV have?
CUREVAC NV (5CV.DE) currently has 825 employees.
What are the support and resistance levels for CUREVAC NV (5CV.DE) stock?
CUREVAC NV (5CV.DE) has a support level at 4.61 and a resistance level at 4.65. Check the full technical report for a detailed analysis of 5CV.DE support and resistance levels.
Is CUREVAC NV (5CV.DE) expected to grow?
The Revenue of CUREVAC NV (5CV.DE) is expected to decline by -84.64% in the next year. Check the estimates tab for more information on the 5CV.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CUREVAC NV (5CV.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of 5CV.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of 5CV.DE, evaluating the profitability, health, valuation and growth aspects
- CUREVAC NV (5CV.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CUREVAC NV (5CV.DE) Sales and EPS estimates to see what analysts future expectations are.
- CUREVAC NV (5CV.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CUREVAC NV (5CV.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- CUREVAC NV (5CV.DE) Stock Chart to make your own analysis
- CUREVAC NV (5CV.DE) Latest news and press-releases to stay up to date.
Does CUREVAC NV (5CV.DE) stock pay dividends?
5CV.DE does not pay a dividend.
When does CUREVAC NV (5CV.DE) report earnings?
CUREVAC NV (5CV.DE) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of CUREVAC NV (5CV.DE)?
The PE ratio for CUREVAC NV (5CV.DE) is 5.7. This is based on the reported non-GAAP earnings per share of 0.81 and the current share price of 4.62 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 5CV.DE.
5CV.DE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to 5CV.DE. When comparing the yearly performance of all stocks, 5CV.DE is one of the better performing stocks in the market, outperforming 92.17% of all stocks.
5CV.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 5CV.DE. 5CV.DE has an excellent financial health rating, but there are some minor concerns on its profitability.
5CV.DE Financial Highlights
Over the last trailing twelve months 5CV.DE reported a non-GAAP Earnings per Share(EPS) of 0.81. The EPS increased by 166.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 34.5% | ||
| ROA | 24.34% | ||
| ROE | 27.94% | ||
| Debt/Equity | 0.05 |
5CV.DE Forecast & Estimates
13 analysts have analysed 5CV.DE and the average price target is 4.22 EUR. This implies a price decrease of -8.66% is expected in the next year compared to the current price of 4.62.
For the next year, analysts expect an EPS growth of -165.87% and a revenue growth -84.64% for 5CV.DE